Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

AAN 2025

The 77th American Academy of Neurology (AAN) Annual Meeting
05–09 April 2025 | San Diego, CA

AAN 2025

The 77th American Academy of Neurology (AAN) Annual Meeting
05–09 April 2025 | San Diego, CA
Coordination of clinical, imaging, and infusion services to manage anti-amyloid therapy for AD 3:04
Coordination of clinical, imaging, and infusion services to manage anti-amyloid therapy for AD
Jeffrey Gelblum • 8 Apr 2025
Advancing anti-amyloid antibody therapies in AD: future directions and improving access 1:52
Advancing anti-amyloid antibody therapies in AD: future directions and improving access
Jeffrey Gelblum • 8 Apr 2025
Barriers and solutions for initiating anti-amyloid therapies for Alzheimer’s disease 3:22
Barriers and solutions for initiating anti-amyloid therapies for Alzheimer’s disease
Jeffrey Gelblum • 8 Apr 2025
The future of immunotherapeutic approaches for the treatment of neurodegenerative diseases 1:58
The future of immunotherapeutic approaches for the treatment of neurodegenerative diseases
Johanne Kaplan • 7 Apr 2025
Promising vaccine targets for alpha-synucleinopathies 1:41
Promising vaccine targets for alpha-synucleinopathies
Johanne Kaplan • 7 Apr 2025
Exploring a vaccine-based approach to targeting Aβ oligomers in Alzheimer’s disease 3:02
Exploring a vaccine-based approach to targeting Aβ oligomers in Alzheimer’s disease
Johanne Kaplan • 7 Apr 2025
Advancing frontotemporal dementia diagnosis through biomarkers and imaging 1:35
Advancing frontotemporal dementia diagnosis through biomarkers and imaging
Bradford Dickerson • 6 Apr 2025
The next steps in antibody development for AD: targeting tau and biomarkers to predict outcomes 1:20
The next steps in antibody development for AD: targeting tau and biomarkers to predict outcomes
Jack Tsao • 8 Apr 2025
The complexity of vaccine development for neurodegenerative diseases 2:33
The complexity of vaccine development for neurodegenerative diseases
Johanne Kaplan • 7 Apr 2025
The clinical experience with lecanemab therapy in patients with MCI and early-stage AD 3:19
The clinical experience with lecanemab therapy in patients with MCI and early-stage AD
Jack Tsao • 8 Apr 2025
From mutation to meaning: revisiting the PSEN1 Alzheimer’s story 12:08
From mutation to meaning: revisiting the PSEN1 Alzheimer’s story
Alberto Espay • 6 Apr 2025
Real-world outcomes with lecanemab in early Alzheimer’s disease 2:10
Real-world outcomes with lecanemab in early Alzheimer’s disease
Justin Moon • 7 Apr 2025
The future of biomarkers in dementia diagnosis and the role of tau-PET imaging 1:10
The future of biomarkers in dementia diagnosis and the role of tau-PET imaging
Marina Scop Medeiros • 8 Apr 2025
Using AI to improve clinical trial screening in neurology 2:06
Using AI to improve clinical trial screening in neurology
Vijaya B. Kolachalama • 8 Apr 2025
The future of AI in neurology 1:12
The future of AI in neurology
Vijaya B. Kolachalama • 8 Apr 2025
The development of a multi-modal AI framework for differential diagnosis of dementia 1:49
The development of a multi-modal AI framework for differential diagnosis of dementia
Vijaya B. Kolachalama • 8 Apr 2025
The content of VJDementia is intended for healthcare professionals